Hospital Acquired Infections, Multidrug Resistant (MDR) Bacteria, Alternative Approaches to Antibiotic Therapy

Bacterial resistance to known and currently used antibiotics represents a growing issue worldwide. It poses a major problem in the treatment of infectious diseases in general and hospital-acquired infections in particular. This is in part due to the overuse and misuse of antibiotics in past decades,...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (206 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 04663nam-a2201165z--4500
001 993545059104498
005 20231214133528.0
006 m o d
007 cr|mn|---annan
008 202207s2022 xx |||||o ||| 0|eng d
035 |a (CKB)5690000000011961 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/87484 
035 |a (EXLCZ)995690000000011961 
041 0 |a eng 
100 1 |a Bostik, Pavel  |4 edt 
245 1 0 |a Hospital Acquired Infections, Multidrug Resistant (MDR) Bacteria, Alternative Approaches to Antibiotic Therapy 
246 |a Hospital Acquired Infections, Multidrug Resistant  
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (206 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a Bacterial resistance to known and currently used antibiotics represents a growing issue worldwide. It poses a major problem in the treatment of infectious diseases in general and hospital-acquired infections in particular. This is in part due to the overuse and misuse of antibiotics in past decades, which led to the selection of highly resistant bacteria and even so-called superbugs – multidrug-resistant (MDR) bacteria. Nosocomial infections, particularly, are often caused by MDR bacterial pathogens and the treatment of such infections is very complicated and extensive, often leading to various side effects, including adverse effects on the natural human microbiome. At the same time, the development of novel antibiotics is lagging with very few new ones in the pipeline. Finding viable alternatives to treat such infections may help to overcome these therapeutic issues. This publication brings novel developments in the field of bacterial resistance, mainly in the hospital settings, adequate antibiotic therapy, and identification of compounds useful to battle this growing issue. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
650 7 |a Epidemiology & medical statistics  |2 bicssc 
653 |a VRE 
653 |a GIT 
653 |a hemato-oncological patients 
653 |a clonality 
653 |a antibiotic stewardship 
653 |a resistance 
653 |a consumption of antibiotics 
653 |a clonal spread 
653 |a Enterococcus faecium 
653 |a Enterococcus faecalis 
653 |a linezolid resistance 
653 |a 23S rRNA 
653 |a optrA 
653 |a carbapenem-resistant Klebsiella pneumoniae 
653 |a carbapenem-resistant Acinetobacter baumannii 
653 |a N-acetylcysteine 
653 |a septic shock 
653 |a critically ill patients 
653 |a newborn 
653 |a infection 
653 |a bacteria 
653 |a antibiotic therapy 
653 |a hops 
653 |a C. difficile 
653 |a rat model 
653 |a Staphylococcus aureus 
653 |a MRSA 
653 |a spa typing 
653 |a MLST 
653 |a SCCmec typing 
653 |a clonal analysis 
653 |a epidemiology 
653 |a cancer patients 
653 |a duration of treatment 
653 |a colistin 
653 |a propensity score analysis 
653 |a multidrug-resistant Acinetobacter baumannii 
653 |a urinary tract infections 
653 |a UTIs 
653 |a MDR 
653 |a Escherichia coli 
653 |a Klebsiella 
653 |a uropathogens 
653 |a AMR 
653 |a antibiotic resistance 
653 |a ESBL-producing Klebsiella pneumoniae 
653 |a urinary tract infection 
653 |a clinical impact 
653 |a economic impact 
653 |a ventilator-associated pneumonia 
653 |a Klebsiella spp. 
653 |a Escherichia spp. 
653 |a pulsed-field gel electrophoresis (PFGE) 
653 |a endogenous infection 
653 |a methicillin-resistant 
653 |a porcine model 
653 |a methicillin-resistant Staphylococcus aureus (MRSA) 
653 |a long term care facilities (LTCF) 
653 |a multidrug resistance (MDR) 
653 |a enterobacterial repetitive intergenic consensus-polymerase chain reaction (ERIC-PCR) 
653 |a ESBL 
653 |a PCR 
653 |a primer 
653 |a antimicrobial resistance 
653 |a infection prevention and control 
653 |a antimicrobial stewardship 
653 |a hospital 
653 |a cluster analysis 
653 |a principal component analysis 
776 |z 3-0365-4418-6 
776 |z 3-0365-4417-8 
700 1 |a Kolar, Milan  |4 edt 
700 1 |a Bostik, Pavel  |4 oth 
700 1 |a Kolar, Milan  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:56:52 Europe/Vienna  |f system  |c marc21  |a 2022-07-14 08:50:39 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337820320004498&Force_direct=true  |Z 5337820320004498  |b Available  |8 5337820320004498